Navigation Links
WuXi PharmaTech to Manufacture Ibalizumab for TaiMed Biologics

SHANGHAI and TAIPEI, Aug. 28, 2012 /PRNewswire-Asia/ -- WuXi PharmaTech (NYSE: WX) today announced that it has a contract manufacturing agreement with TaiMed Biologics Inc. for the manufacture of ibalizumab (TMB-355) in support of Phase 2 and Phase 3 clinical trials globally.  Ibalizumab is a humanized monoclonal antibody and a member of an emerging class of HIV therapies known as viral-entry inhibitors.  This work will be completed at WuXi's biologics manufacturing facilities in China and its biologics testing facilities in the United States.  

"We are pleased that TaiMed Biologics has selected WuXi to manufacture ibalizumab for its global clinical trials because of WuXi's strong technical capabilities and high quality standards," said Edward Hu, Chief Operating Officer of WuXi PharmaTech.  "WuXi's integrated biological drug discovery, development, manufacturing and testing service platform provides our customers with a seamless solution to bring their biologics products to the market globally and in China."

"TaiMed looks forward to working with WuXi to produce clinical-trial supplies of this important new medicine for patients," said James Chang, Chief Executive Officer of TaiMed Biologics. "We are delighted to have such a skilled and reputable partner in WuXi for late-stage manufacturing as we further develop the subcutaneous formulation of our lead product, ibalizumab."

About WuXi PharmaTech

WuXi PharmaTech is a leading pharmaceutical, biotechnology, and medical device R&D outsourcing company, with operations in China and the United States.  As a research-driven and customer-focused company, WuXi PharmaTech provides a broad and integrated portfolio of laboratory and manufacturing services throughout the drug and medical device R&D process.  WuXi PharmaTech's services are designed to assist its global partners in shortening the cycle and lowering the cost of drug and medical device R&D.  WuXi PharmaTech's operating subsidiaries are known as WuXi AppTec.  For more information, please visit

About TaiMed Biologics

TaiMed Biologics, Inc. is a publicly held Taiwanese biotechnology company with the mission to discover, develop and deliver for the global market innovative medicines that help patients prevail over serious infectious diseases. For more information, please visit

WuXi PharmaTech

Aaron Shi (for the media)
Tel: +86-21-5046

Ronald Aldridge (for investors)
Tel: +1-201-585-2048

TaiMed Biologics

James N. Chang, PhD
Chief Executive Officer, TaiMed Biologics

Tel: 1-949-769-6543 (USA), 886-2-2655-8031 (Taiwan)



SOURCE WuXi PharmaTech (Cayman) Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. WuXi PharmaTech Receives GLP Certificate from SFDA for Suzhou Toxicology Facility
2. WuXi PharmaTech Announces Second-Quarter 2012 Results
3. Pharmatech Oncology Receives Phase 2 SBIR Funding for Just-In-Time Enrollment Model
4. WuXi PharmaTech Announces First-Quarter 2012 Results
5. Industry Leading Pharmaceutical News Website Refocused and Relaunched
6. WuXi PharmaTech Files 2011 Annual Report on Form 20-F
7. Pharma Leader Series: Top 20 Antibacterial Drug Manufacturers 2012-2022
8. Pharmaceutical Manufacturers Attempt to Safeguard Business Continuity from Potential Threats and Disasters to Production
9. Statement from Mary Vogt, President of Home Access Health Corporation, manufacturer of the Home Access HIV-1 test system, the only over-the-counter HIV test previously approved by the FDA for at-home use.
10. Thermal Gradient Announces Manufacture of Next Generation DNA Testing Device
11. ADVENTRX Announces Manufacturing Agreement With Patheon to Manufacture ANX-188 Drug Product
Post Your Comments:
(Date:11/24/2015)... Medical has developed specialty tubing for an inexpensive, portable mini-lab ... Africa and Asia ... diagnosis is important to treat those affected and to effectively ... of a portable mini-lab or "lab on a chip", medically-trained ... and perform rapid testing for HIV. They do this by ...
(Date:11/24/2015)... DIEGO , Nov. 24, 2015   Mast ... company leveraging its molecular adhesion and sealant technology (MAST) ... heart failure and stroke, today announced that the Company,s ... present at the Piper Jaffray 27 th Annual ... Eastern Time at the New York Palace hotel in ...
(Date:11/24/2015)... 2015  Depomed, Inc. (NASDAQ: DEPO ) today announced that ... month of December. Date: Wednesday, December 2, 2015 ... --> Date: Wednesday, December 2, 2015 ... --> Piper Jaffray 27th Annual Healthcare Conference ... Location: New York, New York ...
Breaking Medicine Technology:
(Date:11/24/2015)... New Port Richey, FL (PRWEB) , ... November 24, 2015 , ... ... what it deems a growing epidemic as deaths from prescription opioids in the United ... from heroin and cocaine. In 2013 alone, opioids were involved in 37 percent of ...
(Date:11/24/2015)... ... ... American Family Care (AFC), the nation’s leading provider of urgent care and accessible ... Atlanta’s North Point Mall. The clinic is designed to test the concept of addressing ... operate through Dec. 24. , Holiday Pop-Up Clinic , Official Opening November 27, 6 ...
(Date:11/24/2015)... CA (PRWEB) , ... November 24, 2015 , ... Cold Shoulder , LLC launched ... Kickstarter last week and hit their goal of $20,000 in under 10 hours. ... aims to bring the new PRO Weight Loss Vest to the market. , The PRO ...
(Date:11/24/2015)... ... November 24, 2015 , ... Sir ... customer service: the TrustDale certification. The award recognizes good companies for excellence in ... , tile and grout, and hard surface restoration company earned this recognition after ...
(Date:11/24/2015)... ... November 24, 2015 , ... Dr. Kevin Day, local family chiropractor in ... less this holiday season. During the Indiana winter months, Vitamin D deficiency can ... team at AlignLife want to help provide the tools needed to combat it this ...
Breaking Medicine News(10 mins):